SLC5A2 and type 2 diabetes mellitus: Pharmacological management of nutrient-related metabolic disturbances is crucial, as evidenced by the effectiveness of SGLT2 inhibitors such as canagliflozin in lowering the risk of kidney failure and cardiovascular events in patients with type 2 diabetes and established nephropathy (117, 118).